thus precluding the translation of transmembrane and cytoplasmic domains {7, 10, 11).
Constitutive expression of HLA-G translated products has been reprodudbly detected in placenta and thymus. Within the plaeenta, the following cellular subtypes were found to bind HLA-G mAbs by immunohistochemistry: invading extravillous cytotrophoblast (12, (13) (14) (15) endothelial cells lining fetal vessels in the chorionic villi (13) , mesenchymal Hofbauer cells (16) and amnion epithelial cells (17, 18) . Soluble forms of HLA-G have been detected in anmiotic fluids and plasma (18) (19) (20) and, in one report, in some syncytiotrophoblast (16) . HLA-G was also found in some medullary thymic epithelial cells (21, 22) .
Functions of HLA-G are now emerging (1) . HLA-G binds nonamer peptides (23, 24) and is capable of presenting them to CD8+ T cells (25, 26) . HLA-G is the ligand of few killer cell immunoglobuiinlike receptors (2, 27) and modulates HLA-E cell surface expression upon binding to a nonamer derived from the HLA-G leader sequence (28) .
A number of groups have reported the use of HLA-G monoclonal antibodies (mAbs) (14, 16, 18, 23, 29) . Only partial characterization of these reagents has been made and very few comparative studies have been carried out to examine their respective reactivities (1) . Investigations on their potential use in ELISA for the detection of soluble forms of HLA-G are also limited (16, 19) , and little information is available about which antigenic determinant they can recognize. By comparing the reactivity of three HLA-G mAbs in ELISA, we show in this report that they al! identified p2-microglobulin (p2m) retaining soluble HLA-Gl (sHLA-Gl) cDNA, have been already described (13, 35) . 221-sGl cells were similarly transfected with sHLAGl encoding cDNA. ClR-sB7 cell line transfected with sHLA-B7 encoding cDNA, and ClR-mB7, transfected with membrane HLA-B7 encoding cDNA, were kindly provided by Dr. F. C. Grumet (Stanford, CA, USA) and have been previously described (36) . Cell lines were cultured in RPMI 1640 with Glutamax (Life Technologies. Cergy-Pontoise, France) supplemented with 10% FCS, 1 mM sodium pyruvate, 100 rU/ml penicillin and 100 ng/ml streptomycin (Sigma, St Quentin Fallavier, France). Cultures were maintained in a humid atmosphere at 37°C containing 5% CO2. Cell culture supernatants were collected, centrifuged at 1200 rpm for 5 min at 4°C, and stored at -20°C until use. In some cases they were concentrated five times using Macrosep lOK (10 kDa cutoff) centrifugal concentrator (Paul Filtron Corporation, Northborough, MA, USA). 
Material and methods

Monoclonal antibodies
Placental supernatants
Supernatants were prepared as previously desaibed (37) . Briefly, first trimeter and term placentas were obtained from healthy preg- in cell culture supernatants from 2l\, CIR or ClR-sB7 cells (Fig. 2) .
Using 87G as coating mAb, sHLA-G was also detected in culttire supernatants of JAR transfected with a cDNA encoding sHLA-Gl (JAR-sGl), whereas no soluble protein was identified in the culture medium either from tintransfected JAR cells or from JAR cells fransfected with a cDNA encoding membrane HLA-Gl QAR-Gl) (Fig. 2) .
Using serial concentrations of a calibrated sHLA-G reference (20), we established standard curves for 87G and MEM-G/9 HLA-G mAbs (Fig. 3) . Both curves revealed linearity for sHLA-G concentrations in the range of 30 to 260 ng/ml.
We then used the ELISA described above (coating mAb : 87G) to investigate the presence of sHLA-G in few biological fiuids and culttu'e media from placental explants. As shown in Fig. 4A , sHLA-G was identified in amniotic fitiids of healthy pregnant women (19-24 weeks of pregnancy) but not in cord blood sera. Similar results were obtained with MEM-G/9 coating mAb (data not shown). It should be noted that cord blood sera always gave a quite high background in ELISA after coating the plates with isotypic IgG control, which was never the case for amniotic fluids or the different cell culture supernatants (these latter control values have been subsfracted from the values shown in Fig. 4 ). In contrast, by using mAb 90 (anti HLA-A, -B, -C, -G) or B1.23. 2 (anti-HLA-B and -C but not HLA-G) coating mAbs (29) and W6/32 detection mAb, we have observed that the cord blood sera did contain sHLA class Ia molecules (data not shown). sHLA-(; was also detected in culture supernatants from first trimester or term placenta explants (Fig. 4B) .
Based on ELISA standard curves (see Fig. 3 ), we estimated that the concenfrations of sHLA-G in amniotic fluids were in the range of 35 to 130 ng/ml, depending on the samples, and in the range of 30 to 60 ng/ml for placental supernatants. Tbe use of 87G and MEM-G/9 mAbs did not allow to disaiminate between sHLA-G isoforms possibly derived from shedding or proteolytic cleavage of membrane molecules and those retaining intron 4. Therefore we used a conformation independent mAb 16G1 which reacts uniquely with Fig. 2 . Specific detection of sHLA-G with 87G, IVIEMG/9 and BFL.l coating inAbs. (A), 87G (1 ^g/ml), (B), MEM-G/9 (1/5000) and (C), BFL.1 (2 |ig/ml) were coated on microtiter plates and biotinylated W6/32 mAb (10 |ig/nil) was added to revealed the bound sHLA-G molecules (see Materials and methods). To assess the specificity of the EUSA, cell culture supernatants from 221-sGl and JAR-sGl cells were used as positive control and those from JAR. JAR-Gl (which express membrane HLA-Gl), 221, CIR and C1R-SB7 cells were used as negative control. All culture supernatants were used non concentrated, except JAR-sGl which was concentrated 5 times. Results are expressed as means±SD of absorbancy units (492 nm) on ten separate experiments for 87G. seven for BFL.1 and five for MEM-G/9 mAb. ecules. However, combinations using 87G, MEM-G/9 or, to a lesser extent, BFL.l coating mAbs, followed by biotinylated W6/32 detection mAb, gave the strongest specific signals. In all these combinations, SHLA-B7 is never recognized (Fig. 6, left panel) . Interest- None of these HLA-G mAbs did recognize sHLA-B7 present in cultxire supernatant of transfected cells, although it carmot be totally excluded that they also reacted with some unfrequent sHLA class Ia alleies. However, this is unlikely for the following reasons:
firstly, they did not detect any soluble protein in all cord bkxxl samples tested, although we have shown by using mAb 90 or Bl.23.2 coating mAbs that these cord sera did contain some sHLAclass Ia molecules, as already reported by other groups (19); secondly, both 87G (23) and BFL.1 (29) were described not to bind to peripheral blood mononuclear cells of various donors expressing various HLA class la allelea The three HLA-G mAbs used in this study clearly recognized intron 4 retaining sHLA-Gl isoform, since only this species was produced by JAR and 221 transfectants. In contrast, they were unlikely to detect the intron 4 retaining sHLA-G2
shorter form lacking the o2 domain, since W6/32 (used as coating or detection mAb) was shown to recognize an epitope in the a2 domain (31) , absent in sHLA-G2 (7).
sHLA-Gl has been detected in amniotic fluid, which is in accordance with several previous reports (18, 20) . It was shown that at least part of the sHLA-G in amniotic fluid derived from HLA-G cleaved from the membrane (18) . The reactivity of 16G1 mAb specifically raised against intron 4 amino acid that we observed in some amniotic fiuid samples demonstrated that, in addition to shedded or cleaved sHLA-G, intron 4 retaining sHLA-G isoforms were also present.
We did not find any sHLA-G in cord blood, which is in contrast with other findings (19) . However, knowing that human serum does contain p2m-free class I HC (39) and that the HLA-G mAbs used in this study could not detect such a form, it cannot be excluded that p2m-free sHLA-G HC were present in cord blood.
Both types of analysis, performed in ELISA and fiow cytometry, came to the same conclusion that 87G mAb recognizes an epitope localized on the al domain of HLA-G HC. A similar conclusion was drawn from previous investigations (6, 40) . On the contrary, absence of competition between 87G, BFL.1 and MEM-G/9 suggest that the antigenic determinants recognized by these HLA G mAbs are different.
Such HLA-G mAbs should be useful tools to investigate the possible immunoregulatory functions sHLA-G might exert in normal and pathological conditions (41. 42) . Further epitope mapping study of these HLA G reagents together with cristallography of HLA-G molecule may help in more critical interpretation of such future functional studies.
